Please answer it ASAP

Your company want to develop a sustained release oral formulation of an already marketed API. The table below report data for an iv-bolus administration, an oral solution of the API, the already marketed tablet and two candidate new formulations administered to the same subject (BGS, 33 years old, 78 kg).

Table 1 Data provided

	Iv-bolus	Oral solution	Marketed tablet	Sustained-release Tablet A	Sustained-release Tablet B
Dose (mg)	100	200	300	300	300
AUC (mg/L/hr)	365	625	855	893	932
AUMC (mg/L/hr2)	3160.173	5687.5	8379	8947.86	10438.4

From the data provided in Table 1, calculate the following:

	Units	Iv-bolus	Oral solution	Marketed tablet	Sustained-release Tablet A	Sustained-release Tablet B
Absolute F
Relative F (to oral solution)
MRT
MAT
MDT
Half-life
ka

Based on your calculations, what formulation (Tablet A or Tablet B) appears more promising as a sustained release product?

Write a short report according to the provided guidelines.